Kyoto Semiconductor Announces New High-power Photovoltaic Power Converter
13.9.2021 10:00:00 EEST | Business Wire | Press release
Kyoto Semiconductor Co., Ltd. (President and CEO Tsuneo Takahashi, Head office: Fushimi-ku, Kyoto city), a leading optical device solution manufacturer with world-class technologies and Japanese quality, has announced the new high-power photovoltaic power converter, KPC8H-FC.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005220/en/
Kyoto Semiconductor KPC8H-FC High-power Photovoltaic Power Converter (Photo: Business Wire)
It has been 10 years since the company announced its existing model; KPC8-T optical power converter in 2011. Up to now, it has been adopted in various applications using optical power transmission*1 over optical fiber, such as the aircraft equipment, the equipment sensitive to electromagnetic noise, or the equipment in a remote place where the power transmission is difficult. The new high-power photovoltaic power converter KPC8H-FC has improved two features that many KPC8-T customers requested.
|
① |
High Power: By improving the efficiency, the electrical output has been increased 1.3 times compared to our existing product*2 under the same optical input power. In addition, due to the improvement of heat dissipation, the rated value of the maximum optical power input has been tripled compared to that of conventional product*2. The new applications which require higher output can be enabled with KPC8H-FC. |
|
|
② |
Small Form Factor: While the existing product*2 is a pigtail module with single mode optical fiber, KPC8H-FC adopts the small form factor which is integrated in the FC receptacle. It can be directly attached to the operation panel of the equipment (panel mount). Since it saves space, it can contribute to the reduction of the equipment size. |
Sample shipment of the KPC8H-FC high-power photovoltaic power converter is scheduled to begin on September 15, 2021, and mass production is expected to start on April 28, 2022.
For more information on KPC8H-FC, visit: https://www.kyosemi.co.jp/en/products/kpc8h-fc/
*1 Optical power transmission: A method of transmitting power using a photoelectric conversion element for laser light over an optical fiber cable or wireless. Since laser power transmission over optical fiber cables has less loss than metal wires and can be completely electrically isolated, it is possible to transmit power to outdoor equipment or remote equipment where the surge protection is required and the metal wires are difficult to use, or where the electromagnetic noise is strong.
*2 Kyoto Semiconductor’s current photovoltaic power converter KPC8-T: https://www.kyosemi.co.jp/en/products/kpc8-t/
About Kyoto Semiconductor
Kyoto Semiconductor was established in 1980 in Kyoto as a dedicated manufacturer of optical semiconductors. The semiconductors manufactured offer superlative performance and precision, suited for use in optical transmission. They are manufactured end-to-end, including pre- and post-processing, and together with Kyoto Semiconductor’s unique packaging technology, at our location in Japan and made available to customers around the world. Kyoto Semiconductor leads the industry with world-standard technologies for optical device solutions based on Japanese quality and attention to production detail.
Company Website: https://www.kyosemi.co.jp/
*Product names, company names, and organization names mentioned in this press release are trademarks or registered trademarks of their respective companies.
*All contents of this press release are as of the date of publication. Subject to change without notice. Please understand in advance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005220/en/
Contact information
Media Relations, Kyoto Semiconductor Co., Ltd.
Naoko Kodama
Email: Media_relation@kyosemi.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom